Newsletter | October 11, 2025

10.11.25 -- Life Science Leader Best Of September

SEPTEMBER'S BEST FEATURED EDITORIAL

The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens

By Joseph Tucker, Ph.D., CEO, Enveric Biosciences

Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP protection, and patient tolerability.

SEPTEMBER'S BEST INDUSTRY INSIGHTS

5 Tips To Put The Right Systems In Place For Successful Clinical Trials

Before you dive into clinical trials, ask yourself: Is my company operationally ready to handle the complexity? Learn about key upgrades that can help you streamline operations and reduce risk.

Outsourcing Patient Recruitment: What You Need To Know

Sponsors and CROs are increasingly outsourcing patient recruitment to specialized vendors to address the ongoing challenge of meeting initial recruitment targets on time.

The Benefits Of U.S. Biotechs Conducting Clinical Trials In Australia

As U.S. biotech investment continues to rise, cross-border collaboration and trial design innovations are expected to further solidify Australia’s role in the early-stage biotech development pipeline.